[1]杨红彩,郭 志,司同国,等.氩氦冷冻消融术前外周血中性粒细胞与淋巴细胞比值对原发性肝癌患者预后的影响[J].介入放射学杂志,2017,(01):30-34.
 YANG Hong- cai,GUO Zhi,SI Tong- guo,et al.The neutrophil- to- lymphocyte ratio in peripheral blood in patients with hepatocellular carcinoma before argon- helium cryoablation: its influence on the prognosis[J].journal interventional radiology,2017,(01):30-34.
点击复制

氩氦冷冻消融术前外周血中性粒细胞与淋巴细胞比值对原发性肝癌患者预后的影响 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年01期
页码:
30-34
栏目:
非血管介入
出版日期:
2017-01-25

文章信息/Info

Title:
The neutrophil- to- lymphocyte ratio in peripheral blood in patients with hepatocellular carcinoma before argon- helium cryoablation: its influence on the prognosis
作者:
杨红彩 郭 志 司同国 国永飞 杨雪玲 邢文阁 刘 方 刘长富 张炜浩 常 旭
Author(s):
YANG Hong- cai GUO Zhi SI Tong- guo GUO Yong- fei YANG Xue- ling XING Wen- ge LIU Fang LIU Chang- fu ZHANG Wei- hao CHANG Xu
Department of Interventional Radiology, Tumor Hospital, Tianjin Medical University, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China
关键词:
【关键词】 原发性肝癌 中性粒细胞/淋巴细胞比值 氩氦冷冻消融术 预后
文献标志码:
A
摘要:
【摘要】 目的 探讨原发性肝癌(HCC)患者氩氦冷冻消融术前外周血中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对患者预后的影响。方法 回顾性分析72例HCC患者行经皮穿刺氩氦冷冻消融术的相关临床病理资料。根据术前NLR,分为低NLR组(NLR<3.5)和高NLR组(NLR≥3.5),统计分析两组患者术后的总生存期(overall survival,OS),并对其影响预后的危险因素进行单因素和多因素分析。结果 所有患者经氩氦冷冻消融治疗后,中位生存期为22.4个月,其中高NLR组的中位生存期为13.2个月,低NLR组的中位生存期为24.2个月,两组中位生存期差异有统计学意义(P=0.003)。单因素分析显示:原发灶大小、肝功能Child- Pugh分级、白蛋白、总胆红素、胆碱酯酶、NLR是影响HCC患者氩氦冷冻消融术后生存期的相关因素(P<0.05)。多因素分析显示:原发灶大小和NLR是影响HCC患者氩氦冷冻消融术后生存的独立预后因素(P<0.05)。结论 术前外周血中NLR可作为HCC患者行氩氦冷冻消融术的预后指标,肝内原发灶越大、NLR越高,患者预后越差。

参考文献/References:

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61: 69- 90.
[2] 吴孟超, 陈 汉, 沈 锋, 等. 微创在肝癌外科治疗中的地位[J]. 中国微创外科杂志, 2002, 2: 69- 70.
[3] Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil- to- lymphocyte ratio in solid tumors: a systematic review and meta- analysis[J]. J Natl Cancer Inst, 2014, 106: dju124.
[4] 常秀娟, 陆荫英, 曾 珍, 等. 进展期肝癌患者氩氦刀冷冻消融术前中性粒细胞/淋巴细胞比值与术后预后关系研究[J]. 传染病信息, 2015, 28: 241- 243.
[5] Yashiro H, Nakatsuka S, Inoue M, et al. Factors affecting local progression after percutaneous cryoablation of lung tumors[J]. J Vasc Interv Radiol, 2013, 24: 813- 821.
[6] Niu LZ, He LH, Zhou L, et al. Percutaneous cryoablation and 125I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases[J]. Zhonghua Zhong Liu Za Zhi, 2012, 34: 940- 944.
[7] Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation[J]. AJR Am J Roentgenol, 2013, 200: 461- 466.
[8] Kerkar S, Carlin AM, Sohn RL, et al. Long- term follow up and prognostic factors for cryotherapy of malignant liver tumors[J]. Surgery, 2004, 136: 770- 779.
[9] Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil- to- lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis[J]. Ann Surg, 2013, 258: 301- 305.
[10] Motomura T, Shirabe K, Mano Y, et al. Neutrophil- lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J]. J Hepatol, 2013, 58: 58- 64.
[11] Xiao WK, Chen D, Li SQ, et al. Prognostic significance of neutrophil- lymphocyte ratio in hepatocellular carcinoma: a meta- analysis[J]. BMC Cancer, 2014, 14: 117.
[12] da Fonseca LG, Barroso- Sousa R, Bento Ada S, et al. Pre- treatment neutrophil- to- lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Med Oncol, 2014, 31: 264.
[13] Xu X, Chen W, Zhang L, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Chin Med J (Engl), 2014, 127: 4204- 4209.
[14] Wei K, Wang M, Zhang W, et al. Neutrophil- lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib[J]. Med Oncol, 2014, 31: 969.
[15] Xiao GQ, Yan L, Yang J. How to select suitable hepatocellular carcinoma for liver transplantation by preoperative neutrophil
- lymphocyte ratio[J]. Hepatogastroenterology, 2014, 61: 2077- 2083.

相似文献/References:

[1]高 嵩,朱旭,杨仁杰,等. TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
 ,,et al. TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin, 5fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].journal interventional radiology,2012,(01):377.
[2]程洪涛,郭晨阳,黎海亮,等.TACE联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
 ,,et al.TACE combined with CTguided percutaneous radiofrequency ablation for the treatment of primary hepatocellular carcinomas: an analysis of factors affecting the therapeutic result [J].journal interventional radiology,2012,(01):216.
[3]张晓前,郭 鹏,党之俊,等.金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J].介入放射学杂志,2012,(03):249.
 ,,et al.Kinglong capsules combined with interventional therapy for hepatocellular carcinomas: clinical observation [J].journal interventional radiology,2012,(01):249.
[4]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合CT引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
 ,,et al.Sequential treatment with TACE and CTguided RFA for small and moderate sized HCC [J].journal interventional radiology,2012,(01):301.
[5]姚全军,胡鸿涛,黎海亮,等.C臂CT成像在乏血供原发性肝癌诊疗中的临床应用[J].介入放射学杂志,2012,(04):305.
 ,,et al.The clinical application of C arm CT imaging in diagnosing and treating hypovascular primary hepatic carcinomas [J].journal interventional radiology,2012,(01):305.
[6]刘 昕,吕维富,鲁 东,等. 动脉介入栓塞治疗肝癌破裂出血[J].介入放射学杂志,2012,(07):586.
 LIU Xin,LV Wei- fu,LU Dong,et al. Interventional treatment of hepatic bleeding due to spontaneous rupture of hepatocellular carcinoma[J].journal interventional radiology,2012,(01):586.
[7]张志良,杨学东,温阿明,等. 经动脉化疗栓塞联合伽玛刀治疗原发性肝癌的疗效评价[J].介入放射学杂志,2012,(07):596.
 ZHANG Zhi- liang,YANG Xue- dong,WEN A-ming,et al. Evaluation of TACE combined with gamma?蛳 knife radiotherapy for primary hepatocellular carcinoma[J].journal interventional radiology,2012,(01):596.
[8]赵许亚,周 石.TACE联合经皮瘤内注射碘油吡柔比星乳剂治疗中晚期肝癌疗效分析[J].介入放射学杂志,2012,(08):675.
 ZHAO Xu- ya,ZHOU Shi.. Transcatheter artery chemoembolization combined with percutaneous intratumoral injection of Lipiodol emulsion of pirarubicin for advanced hepatocellular carcinomas: an analysis of clinical efficacy[J].journal interventional radiology,2012,(01):675.
[9]王少雷,李 森,魏 宏,等.奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究[J].介入放射学杂志,2012,(09):738.
 WANG Shao- lei,LI Sen,WEI Hong,et al. Interventional chemoembolization therapy of primary hepatocellular carcinoma: a comparative study between oxaliplatin and therarubicin[J].journal interventional radiology,2012,(01):738.
[10]骆俊朋,胡鸿涛,郭晨阳,等.吉西他滨热化疗灌注联合卡铂化疗栓塞治疗原发性肝癌临床应用研究[J].介入放射学杂志,2013,(06):470.
 LUO Jun? peng,HU Hong? tao,GUO Chen? yang,et al. Hyperthermochemotherapy by using heated gemcitabine perfusion combined with transcatheter arterial chemoembolization of carboplatin for primary liver carcinomas[J].journal interventional radiology,2013,(01):470.

备注/Memo

备注/Memo:
(收稿日期:2016-03-04)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-01-17